TMCI Oct 2024 7.500 call
| Previous close | 0.1000 |
| Open | 0.1000 |
| Bid | 0.0000 |
| Ask | 0.1500 |
| Strike | 7.50 |
| Expiry date | 2024-10-18 |
| Day's range | 0.1000 - 0.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | 16 |
Insider MonkeyTreace Medical Concepts (TMCI) Slid on Reduced Guidance
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second-quarter 2024 investor letter. A copy of the letter can be downloaded here. In the quarter the fund returned -1.59% (gross) and -1.83% (net), compared to a -2.92% return for the Russell 2000 Growth Index. The equity markets performed well in […]
GlobeNewswireTreace Highlights New Product Innovations and Updated Clinical Study Data at the American Orthopaedic Foot & Ankle Society Annual Meeting 2024
PONTE VEDRA, Fla., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced it will highlight new product innovations and present new interim data for the ALIGN3D™ and Mini3D™ Lapiplasty® clinical studies at the American Orthopaedic Foot &
- GlobeNewswire
Treace Announces Participation in the Morgan Stanley 22nd Annual Global Healthcare Conference
PONTE VEDRA, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global
